Higher NSUN2 expression is linked to more advanced cancer stages and heightened drug resistance, while elevated YBX1 expression correlates with poorer patient survival (Liu L. et al., 2024; Niu et al., 2022; Su et al., 2021). Here, NSUN2 is linked to cancer.